<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01477203</url>
  </required_header>
  <id_info>
    <org_study_id>FA103FC001</org_study_id>
    <secondary_id>2011-004860-31</secondary_id>
    <nct_id>NCT01477203</nct_id>
  </id_info>
  <brief_title>Multimodal Assessment of Neurobiological Markers for Psychiatric Disorders</brief_title>
  <acronym>MAN-BIOPSY</acronym>
  <official_title>Multimodal Assessment of Neurobiological Markers for Psychiatric Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      MAN-BIOPSY pursues the concrete research question whether novel biological and&#xD;
      psycho-physiological clusters or categories can be defined to improve treatment and minimize&#xD;
      side effects in psychiatry, based on a synopsis of physiological, behavioural, genetic and&#xD;
      endocrinological parameters. One major aspect of our research approach is its focuses on the&#xD;
      identification of dysfunctions in fundamental information processing mechanisms and&#xD;
      neurocomputational mechanisms, and is not restricted to symptom-oriented tasks.&#xD;
&#xD;
      The main objectives of MAN-BIOPSY are therefore&#xD;
&#xD;
        -  to identify biological and psycho-physiological parameters for major depressive&#xD;
           disorders and anxiety disorders, and&#xD;
&#xD;
        -  to identify predictive markers for treatment response and type/severity of side effects&#xD;
           for these disorders.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SSRI induced changes in BOLD (blood oxygen level dependent) response over time</measure>
    <time_frame>4 vears</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>SSRI induced changes in ERPs (event-related potentials) over time</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>biochemical data</measure>
    <time_frame>4 years</time_frame>
    <description>these include steroid hormone levels, vitamins, etc.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">289</enrollment>
  <condition>Major Depressive Disorder (MDD)</condition>
  <condition>Anxiety Disorder</condition>
  <arm_group>
    <arm_group_label>Escitalopram</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 Major Depressive Disorder Patients and 50 Anxiety Disorder Patients will receive Escitalopram as medication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Remitted Patients</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Controls</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram</intervention_name>
    <description>2-4 weeks, 5-10mg, max 20mg</description>
    <arm_group_label>Escitalopram</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for patients:&#xD;
&#xD;
          -  DSM-IV-TR diagnosis of MDD or an anxiety disorder (excluding PTSD, specific phobias,&#xD;
             and bipolar disorder) by a structured clinical interview (SCID)&#xD;
&#xD;
          -  aged 18 to 50 years&#xD;
&#xD;
          -  drug-free within the last three months prior inclusion&#xD;
&#xD;
          -  willingness and competence to sign the informed consent form&#xD;
&#xD;
        Inclusion Criteria for remitted subjects:&#xD;
&#xD;
          -  a previous DSM-IV-TR diagnosis of MDD or an anxiety disorder (excluding PTSD, specific&#xD;
             phobias, and bipolar disorder) but no symptoms at present, determined by SCID&#xD;
&#xD;
          -  aged 18-50 years&#xD;
&#xD;
          -  drug-free within the last three months prior inclusion&#xD;
&#xD;
          -  willingness and competence to sign the informed consent form&#xD;
&#xD;
        Inclusion Criteria for healthy control subjects:&#xD;
&#xD;
          -  Inclusion criteria for healthy control subjects are&#xD;
&#xD;
          -  willingness and competence to sign the informed consent form&#xD;
&#xD;
          -  aged 18-50 years&#xD;
&#xD;
          -  drug-free&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  concomitant major internal or neurological illness&#xD;
&#xD;
          -  concomitant psychiatric disorders (except depression and anxiety for patients,&#xD;
             excluding PTSD, claustrophobia and bipolar disorder)&#xD;
&#xD;
          -  ingestion of any antipsychotic, antidepressant, or anti-anxiety agent within the last&#xD;
             three months prior to the screening visit&#xD;
&#xD;
          -  current substance abuse&#xD;
&#xD;
          -  failure to comply with the study protocol or to follow the instructions of the&#xD;
             investigating team&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical University of Vienna, Department for Psychiatrie and Psychotherapie</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <link>
    <url>http://www.meduniwien.ac.at/neuroimaging/</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://biol-psy.univie.ac.at/</url>
    <description>Related Info</description>
  </link>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>November 15, 2011</study_first_submitted>
  <study_first_submitted_qc>November 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2011</study_first_posted>
  <last_update_submitted>September 13, 2016</last_update_submitted>
  <last_update_submitted_qc>September 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Rupert Lanzenberger</investigator_full_name>
    <investigator_title>A/Prof.PD.Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Problem Behavior</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

